CASTLE BIOSCIENCES, INC. Proceeds from Sale and Maturity of Marketable Securities
CASTLE BIOSCIENCES, INC. (CSTL) reported Proceeds from Sale and Maturity of Marketable Securities of $80.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-07-30
- CASTLE BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $41.00M, a 6.82% decline year-over-year.
- CASTLE BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $39.10M, a 7.71% increase year-over-year.
- CASTLE BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $54.00M, a 10.96% decline year-over-year.
- CASTLE BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $54.90M, a 49.18% increase year-over-year.
- CASTLE BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for fiscal 2025 was $189.20M, a 2.88% increase from fiscal 2024.
- CASTLE BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for fiscal 2024 was $183.90M, a 1.39% decline from fiscal 2023.
- CASTLE BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for fiscal 2023 was $186.50M.
- CASTLE BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for fiscal 2022 was $0.00.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $41.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $80.10M 10-Q · filed 2026-07-30 | $134.10M derived: sum of 3 quarters · filed 2026-07-30 | $189.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $39.10M 10-Q · filed 2026-05-06 | $93.10M derived: sum of 2 quarters · filed 2026-05-06 | $148.00M derived: sum of 3 quarters · filed 2026-05-06 | $192.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $54.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $108.90M derived: sum of 2 quarters · filed 2026-02-26 | $152.90M derived: sum of 3 quarters · filed 2026-07-30 | $189.20M 10-K · filed 2026-02-26 |
| 2025-09-30 | $54.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $98.90M derived: sum of 2 quarters · filed 2026-07-30 | $135.20M 10-Q · filed 2025-11-03 | $195.85M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $44.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $80.30M 10-Q · filed 2026-07-30 | $140.95M derived: sum of 3 quarters · filed 2026-07-30 | $177.75M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $36.30M 10-Q · filed 2026-05-06 | $96.95M derived: sum of 2 quarters · filed 2026-05-06 | $133.75M derived: sum of 3 quarters · filed 2026-05-06 | $170.00M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $60.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $97.45M derived: sum of 2 quarters · filed 2026-02-26 | $133.70M derived: sum of 3 quarters · filed 2026-02-26 | $183.90M 10-K · filed 2026-02-26 |
| 2024-09-30 | $36.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $73.05M derived: sum of 2 quarters · filed 2025-11-03 | $123.25M 10-Q · filed 2025-11-03 | $171.75M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $36.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $86.45M 10-Q · filed 2025-08-04 | $134.95M derived: sum of 3 quarters · filed 2026-02-26 | $177.95M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $50.20M 10-Q · filed 2025-05-05 | $98.70M derived: sum of 2 quarters · filed 2026-02-26 | $141.70M derived: sum of 3 quarters · filed 2026-02-26 | $186.70M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $48.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $91.50M derived: sum of 2 quarters · filed 2026-02-26 | $136.50M derived: sum of 3 quarters · filed 2026-02-26 | $186.50M 10-K · filed 2026-02-26 |
| 2023-09-30 | $43.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $88.00M derived: sum of 2 quarters · filed 2024-11-04 | $138.00M 10-Q · filed 2024-11-04 | $138.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $45.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $95.00M 10-Q · filed 2024-08-05 | $95.00M derived: sum of 3 quarters · filed 2025-02-27 | $95.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $50.00M 10-Q · filed 2024-05-02 | $50.00M derived: sum of 2 quarters · filed 2025-02-27 | $50.00M derived: sum of 3 quarters · filed 2025-02-27 | $50.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $0.00 10-Q · filed 2023-08-02 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |